 |
 |
|
Epidemiology
The prevalence of Type I HD in the general population has been estimated to range from 1 in 2,000
to 1 in 20,000 individuals, although the range is more commonly reported to be 1 in 2,000 to 1 in
5,000. One estimate citing a prevalence of 1 in 5,000 was derived from unpublished observations
made during a screening study of 25,000 women, of which 5 were found to have HD. Recently, an
analysis of 9 previously published general prevalence studies estimated that the incidence of Type I
HD in the adult population ranges from 1 in 1,841 (0.05%) to 1 in 2,801 (0.04%).
Interestingly, a survey of 4,000 healthy blood donors evaluating both Type I and Type II mutations
indicated that Type II HD could be as much as 10 to 15-fold as prevalent than Type I HD.
How are HD patients managed today? 
References
Internal Report: MetaWorks Inc., "Hereditary Deficiency of Antithrombin III:
Prevalence and Thrombosis Prevention: A Systematic Review of the Literature"; April 12, 2002.
Abildgaard, U. (1981) Antithrombin and related inhibitors of coagulation.
Recent advances in blood coagulation 3:151-173.
Tait, R. C., Walker, I. D., Perry, D. J., Islam, S. I., Daly, M. E., McCall, F., Conkie, J. A. Carrell, R. W.
(1994) Prevalence of antithrombin deficiency in the healthy population. Br J Haematol. 87:106-112.
van Boven, H.H., and Lane, D. A. (1997) Antithrombin and its inherited deficiency states.
Seminars in Hematology 34:188-204.
|
|
|
|
